Loading clinical trials...
Loading clinical trials...
A Two-part Open Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene Compared to Intranasal Naloxone in Healthy Volunteers Under Steady State Opioid Agonism
Conditions
Interventions
Nalmefene hydrochloride
Naloxone hydrochloride
Locations
1
United States
PRA Health Sciences
Salt Lake City, Utah, United States
Start Date
March 30, 2021
Primary Completion Date
March 14, 2022
Completion Date
March 14, 2022
Last Updated
July 14, 2025
NCT06993636
NCT05539872
NCT07237477
NCT06072170
NCT01226316
NCT04911270
Lead Sponsor
Opiant Pharmaceuticals Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions